Ultragenyx Pharma (RARE) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Ultragenyx Reports First Quarter 2016 Financial Results and Corporate Update
May 9, 2016 4:06 PM EDTNOVATO, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended March 31, 2016.
We are continuing to make progress with our pipeline, including our recent interim data from the Phase 2 study of KRN23 showing serum phosphorus increases and a preliminary look on bone health in patients with tumor-induced osteomalacia, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. As a company... More
